DOI QR코드

DOI QR Code

Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma

Li, Yong;Li, Da-Jiang;Chen, Jian;Liu, Wei;Li, Jian-Wei;Jiang, Peng;Zhao, Xin;Guo, Fei;Li, Xiao-Wu;Wang, Shu-Guang

  • Published : 2015.04.29

Abstract

Objective: To explore the application of joint detection of serum AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma (CC). Materials and Methods: The levels of serum AFP, CA19-9, CA125 and CEA of both 30 patients with CC and 30 patients with hepatocellular carcinoma (HCC) were assessed. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic effects of single and joint detection of those 4 kinds of tumor markers for CC. Results: The levels of serum CA19-9, CA125 and CEA in CC patients were higher than that in HCC patients,whereas that of serum AFP was significantly lower s. The area under ROC curve of single detection of serum AFP, CA19-9, CA125 and CEA were 0.05, 0.86, 0.84 and 0.83, with the optimal cutoff values of 15.4 ng/ml, 125.1 U/ml, 95.7 U/ml and 25.9 ng/ml, correspondingly, and the percentage correct single diagnosis was <79%. With joint detection, the diagnostic effect of combined AFP, CA19-9, CA125 and CEA was the highest, with an area under the ROC curve of 0.94 (95%CI 0.88~0.99). Conclusions: Single detection of serum CA19-9, CA125 and EA is not meaningful. The sensitivity, specificity, the rate of correct diagnosis and the area under ROC curve of joint detection of AFP, CA19-9, CA125 and CEA are highest, indicating that the joint detection of these 4 tumor markers is of great importance in the diagnosis of CC.

Keywords

Cholangiocarcinoma;hepatocellular carcinoma;tumor markers;identification and diagnosis;ROC curve

References

  1. Al-Bahrani R, Nagamori S, Leng R, et al (2015). Differential Expression of Sonic Hedgehog Protein in Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Pathol Oncol Res, Epub ahead of print.
  2. Asayama Y, Nishie A, Ishigami K, et al (2015). Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol, 21, 96-104. https://doi.org/10.5152/dir.2014.13013
  3. Charatcharoenwitthaya P, Enders FB, Halling KC, et al (2008). Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 48, 1106-17. https://doi.org/10.1002/hep.22441
  4. Chaiteerakij R, Harmsen WS2, Marrero CR, et al (2014). A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol, 109, 1881-90. https://doi.org/10.1038/ajg.2014.327
  5. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer.Asian Pac J Cancer Prev, 14, 3855-9. https://doi.org/10.7314/APJCP.2013.14.6.3855
  6. Hemming AW, Reed AI, Fujita SMP, et al (2005). Surgical management of hilar cholangiocarcinoma. Ann Surg, 241, 693-702. https://doi.org/10.1097/01.sla.0000160701.38945.82
  7. Kim SW, Lim do H, Park HC, et al (2015). Salvage radiation therapy for isolated local recurrence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. Ann Surg Oncol, 22, 1308-14. https://doi.org/10.1245/s10434-014-4146-z
  8. Liu Y, Qian HX, Zhuo M, et al (2013). Influences of Resveratrol on the Proliferation of Cholangiocarcinoma Cells and Expression of p21 and p27 Proteins. J Int Transl Med, 1, 201-4.
  9. Lumachi F, Lo Re G, Tozzoli R, et al (2014). Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Anticancer Res, 34, 6663-7.
  10. Liu LK, Shao MW, Ma L, et al (2015). Values of seven tumor markers in identification and diagnosis of esophageal carcinoma accompanied by neuroendocrine differentiation. J Int Transl Med, 3, 541-5.
  11. Mohammad-Alizadeh AH, Ghobakhlou M, Shalmani HM, et al (2012). Cholangiocarcinoma: an-eight-year experience in a tertiary-center in Iran. Asian Pac J Cancer Prev, 13, 5381-4. https://doi.org/10.7314/APJCP.2012.13.11.5381
  12. Nakeeb A, Lipsett PA, Lillemoe KD, et al (1996). Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg, 171, 147-53. https://doi.org/10.1016/S0002-9610(99)80090-7
  13. Nanashima A, Sumida Y, Abo T, et al (2007). Patient outcome and prognostic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology, 54, 2337-42.
  14. Patel AH, Harnois DM, Klee GG, et al (2000). The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol, 95, 204-7. https://doi.org/10.1111/j.1572-0241.2000.01685.x
  15. Qu K, Liu SN, Chang HL, et al (2012). Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev, 13, 1317-20. https://doi.org/10.7314/APJCP.2012.13.4.1317
  16. Sheen-Chen SM, Sun CK, Liu YW, et al (2007). Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci, 52, 3140-2. https://doi.org/10.1007/s10620-006-9164-7
  17. Sheen-Chen SM, Sun CK, Liu YW, et al (2007). Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci, 52, 3140-2. https://doi.org/10.1007/s10620-006-9164-7
  18. Shao L, Hong W, Zhang YP (2013). Survival model established by combined serum tumor markers in predicating the effect of erlotinib on patients with recurrent non-small Cell Lung Cancer. J Int Transl Med, 1, 185-93.
  19. Taketa K, Okada S, Win N, et al (2002). Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama, 56, 317-20.
  20. Tang X, Zhang J, Chen Y, et al (2014). Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma. Chin J Oncol, 36, 662-6.
  21. Tyson GL, Ilyas JA, Duan Z, et al (2014). Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci, 59, 3103-10. https://doi.org/10.1007/s10620-014-3276-2
  22. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6. https://doi.org/10.7314/APJCP.2014.15.2.703
  23. Zuckerman E, Lanir A, Sabo E, et al (1999). Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol, 94, 1613-8. https://doi.org/10.1111/j.1572-0241.1999.01152.x

Cited by

  1. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC) vol.48, pp.3, 2015, https://doi.org/10.3892/ijo.2015.3316
  2. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile vol.10, pp.6, 2016, https://doi.org/10.2217/bmm-2015-0062
  3. Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review vol.98, pp.6, 2018, https://doi.org/10.4269/ajtmh.17-0879
  4. Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma vol.2019, pp.1875-8630, 2019, https://doi.org/10.1155/2019/6016931